
There may be differences between this version and the published version. You are advised to consult the publisher’s version if you wish to cite from it.

http://eprints.gla.ac.uk/193782/

Deposited on 23 August 2019

Enlighten – Research publications by members of the University of Glasgow
http://eprints.gla.ac.uk
**Chronic Obstructive Pulmonary Disease and Heart Failure: A Breathless Conspiracy**

Short title:- COPD in Heart Failure

~Pierpaolo Pellicori MD,FESC, ~John GF Cleland MD, FRCP, FESC, FACC ,
*Andrew L Clark MA, MD, FRCP

~Robertson Institute of Biostatistics and Clinical Trials Unit, University of Glasgow,
University Avenue, Glasgow, G12 8QQ.

*Department of Cardiology, Castle Hill Hospital, Hull York Medical School (at University of Hull), Kingston upon Hull, HU16 5JQ, UK

Corresponding author: Dr Pierpaolo Pellicori

Robertson Institute of Biostatistics and Clinical Trials Unit, University of Glasgow,
University Avenue, Glasgow, G12 8QQ, UK.

Tel: +44 0 141 330 4744; Fax: +44 0 141 330 5094

Email: pierpaolo.pellicori@glasgow.ac.uk

**Conflict of interest:** none declared.
Synopsis

Heart failure (HF) and chronic obstructive pulmonary disease (COPD) are both common causes of breathlessness and often conspire to confound accurate diagnosis and optimal therapy. Risk factors (such as aging, smoking and obesity) and clinical presentation (for instance, cough and breathlessness on exertion) can be very similar, but the treatment and prognostic implications are very different. In this review, we discuss the diagnostic challenges in individuals with exertional dyspnoea. We also highlight the prevalence, clinical relevance and therapeutic implications of a concurrent diagnosis of COPD and heart failure.

Keywords: COPD, heart failure, natriuretic peptides, diagnosis, review, therapy.

Key Points:

- COPD and heart failure are both common and share many risk factors
- Heart failure and COPD frequently co-exist and such patients have a poor prognosis
- Determining whether breathlessness is due predominantly to lung or heart disease can be difficult; missed diagnoses are common
- The combined effect of treatments for HFrEF on outcome is large and therefore the diagnosis should not be missed
- COPD may deter the introduction or dose of beta-blockers, a key treatment for HFrEF
- Treatments do not substantially alter outcomes for COPD or HFpEF
Introduction

Heart failure (HF) and chronic obstructive pulmonary disease (COPD) are increasingly common and often co-exist. Together they probably cause or complicate about 10% of all hospital admissions. However, perhaps fewer than half of patients who have these conditions have appropriate investigation and diagnosis. Furthermore, the diagnosis of one condition may obscure the presence of the other (1, 2). HF and COPD have much in common, including risk factors (for instance, a lifelong history of smoking and obesity), symptoms (breathlessness and cough) and clinical signs (lung crackles and peripheral oedema). Differentiating between the two conditions is a diagnostic challenge, but their correct identification is essential: the correct treatment will improve the long-term outcome of many patients with heart failure, whereas there is little treatment that has a profound impact on outcome for COPD (3, 4).

In this review, we will discuss the diagnostic challenges in distinguishing COPD from chronic heart failure in patients with exertional dyspnoea. We will also discuss the prevalence, clinical relevance and therapeutic implications associated with a concurrent diagnosis of COPD and heart failure.

COPD and heart failure: a diagnostic challenge

Clinical history and physical examination

An accurate clinical history usually leaves more doubts than certainties in a breathlessness patient, as signs and symptoms are not specific for either condition. Advanced age increases the risk of having both COPD and HF. Many of those who report dyspnoea on exercise are or
have been smokers, many are obese and many have coronary artery disease. Cough is frequent, and can be due to COPD, heart failure or use of angiotensin-converting-enzyme inhibitors (ACE-I). Clinical signs of air flow limitation (such as wheeze) or high cardiac filling pressure (such as lung crackles, or raised jugular vein pressure) lack specificity and are common only when disease is severe (5,6). Non-intentional weight loss, malnutrition, and cachexia are also common in the more advanced stages of either COPD or HF (7, 8).

Chest-x ray and other radiological findings
A normal chest X-ray does not rule out a diagnosis of COPD or chronic HF (9). Abnormal findings are non-specific except, perhaps, when there is frank pulmonary oedema. However, other causes of cough and exertional breathlessness can be diagnosed on a chest X-ray, such as lung cancer, tuberculosis and pulmonary fibrosis. An X-ray should always be considered.

Electrocardiography
A normal ECG excludes heart failure for practical purposes, but not COPD (10). Although many subtle ECG changes have been reported in patients with COPD, their clinical relevance has not been demonstrated (11). Prompt identification of atrial fibrillation, a common ECG finding in both conditions, is important as anti-coagulation is usually indicated to prevent stroke.

Spirometry
A ratio of forced expiratory volume in the first second (FEV1) to forced vital capacity (FVC) of less than 70% after administration of a bronchodilator is the key diagnostic criterion for COPD (12). This definition seems quite straightforward, but spirometry can be easily
misinterpreted, leading to inappropriate diagnosis and treatment (13). Up to 25% of patients who meet the spirometric criterion for COPD will have a result within the normal range on repeat testing without receiving any treatment that could explain the difference (14, 15). On the other hand, a substantial proportion of current, or past, smokers with respiratory symptoms, apparent exacerbations, and exercise limitation has evidence of airway disease on computed tomography scans, despite normal spirometry (16). The FEV1/FVC ratio also declines with age and heart failure may cause further reductions.

**Biomarkers**

With rare exceptions (such as constrictive pericarditis), when intra-cardiac pressures rise or renal water and salt retention occur leading to fluid overload, the heart produces natriuretic peptides (NPs) as a counter-regulatory strategy designed to cause natriuresis and vasodilation. Increasing plasma concentrations of NPs are the single most powerful predictor of adverse outcome in patients with heart failure, regardless of left ventricular ejection fraction (17, 18). A normal plasma concentration of NPs rules out serious cardiac dysfunction (in constrictive pericarditis, plasma concentrations of NPs are lower than expected from the clinical picture but rarely normal). The diagnostic utility of NPs is currently recognised by all international guidelines on heart failure, including the National Institute for Health and Care Excellence and the European Society for Cardiology, to rule out important cardiac dysfunction in patients with suspected HF, acute or chronic (3).

Screening studies suggest that up to 50% of patients with COPD have increased plasma concentrations of NPs, although no large definitive study exists (table 1) (19-22). Raised plasma NPs in patients with COPD predict a higher mortality, whether or not they have received a
diagnosis of HF (23, 24). For patients with COPD, increased plasma concentrations of high-sensitivity troponin-I, suggesting ongoing myocardial damage, are also associated with high rates of CV events, but not with exacerbations of COPD (25). No blood biomarkers are currently recommended for the identification of people with COPD. Patients with an elevated plasma concentration of NP should be investigated further, usually by echocardiography.

**Echocardiography**

Cardiac imaging (most commonly echocardiography) is an essential investigation for breathless patients who have an elevated plasma NP or in whom a cardiac contribution to breathlessness is suspected or needs to be excluded. It is important not to miss patients with a reduced left ventricular ejection fraction or severe valve disease, for which highly effective treatments exist. If these abnormalities are excluded, a dilated left atrium implies that the patient has abnormal left ventricular diastolic function and suggests the diagnosis of HFpEF. An echocardiogram should be considered in patients with an exacerbation of COPD, as around 25% of patients will have an important, potentially treatable, underlying heart problem (26, 27).

**How common are COPD and heart failure?**

Everyone gets breathless with sufficient exertion. Breathlessness precipitated by modest levels of exertion that a healthy young person can easily manage is very common, but is frequently not reported or investigated. Many subjects, or sometimes their doctors, attribute exertional dyspnoea to simply “getting older” or “being unfit or fat”. Consequently, many
cases of heart failure and/or COPD are not diagnosed until symptoms or signs become severe enough to require a hospital admission. Use of a loop diuretic is also common in primary care as treatment for exertional dyspnoea or ankle swelling: its use might temporarily mask symptoms of heart failure. Initiation of loop diuretics should prompt further investigation of cardiac function (28). Robust, objective criteria to identify, or rule out, cardiac or lung disease as a cause of breathlessness are, with the exception of NPs, lacking. Thus, the reported prevalence of COPD and HF varies substantially, depending on the characteristics of the population studied, the context and period of time in which data were collected, the geographic area and exposure to different environmental risk factors and, most importantly, the diagnostic criteria used to define HF and COPD.

At least 5% of the adult population is said to have COPD, whilst the prevalence of heart failure is perhaps 1-2%. Many reports suggest that a large proportion of breathlessness patients have both conditions (tables 2, 26, 29-36 and 337-48). It’s worth noting that the diagnosis of “heart failure” includes those with either a reduced (HFrEF) or preserved (HFpEF) left ventricular ejection fraction on imaging, which have a similar prevalence.

**Prevalence and prognostic relevance of HF in people with COPD**

In surveys of COPD, heart failure is usually reported in <20% of patients (table 2). Despite the high prevalence of ischaemic heart disease, smoking, and echocardiographic abnormalities in patients with COPD, COPD itself is, surprisingly, not strongly associated with heart failure in epidemiological studies. Perhaps once a diagnosis of COPD is made, clinicians do not look for other problems to explain symptoms. However, missing a diagnosis of heart failure may have important consequences. In a cohort of 404 patients aged >65 years with COPD diagnosed in primary care, a detailed cardiovascular examination identified
previously undiagnosed heart failure in 21%, of whom about 50% had HFrEF and 50% HFrEF (35). A diagnosis of HF approximately doubled the risk of mortality in models adjusted for age and other comorbidities. Of those with COPD who were thought not to have HF, 22% were treated with a diuretic, and ~1/3 had an NT-proBNP >125 ng/l, suggesting that many of these patients also had heart failure.

Amongst 1,664 ambulatory patients with COPD enrolled in a multicentre registry in Spain and the USA (BODE), the prevalence of self-reported HF, supported by review of medical records, was ~16%, which was associated with a 33% increase in mortality (29). A recent analysis of electronic health records from Sweden, which included data from primary and secondary care on ~90,000 patients aged≥ 35 years, showed that, compared to those with COPD alone (n=885, 1%), those who had HF as a coded co-diagnosis (n=99, 10%) had a 7-fold higher mortality (36).

**Prevalence and prognostic relevance of COPD in people with HF**

The prevalence of COPD amongst patients with HF ranges from 10-20% in large trials and registries where COPD was either self-reported by patients or based on the opinion (non-standardized) of researchers (table 3). In smaller studies that used lung function tests to evaluate airflow obstruction objectively, up to 50% of patients with HF have abnormal spirometry. This wide discrepancy might suggest that the diagnosis of COPD is often missed, perhaps because cardiologists pay little attention to airway disease in the presence of a more deadly, but treatable, condition. However, it is also possible that HF has effects on the lung that mimic the effects of COPD leading to over-diagnosis. Interstitial lung oedema can compress alveoli and distal airways; cardiomegaly or pleural effusion can reduce the intra-
thoracic space and compress lung volumes; decreased respiratory muscle strength can reduce inspiratory and expiratory forces; frailty may impair the ability to perform spirometry accurately and normal values in those aged >80 years of age are not well-defined, which might lead to over-diagnosis by spirometry (49). Moreover, effective treatment for heart failure can normalise spirometry and reduce hospitalisations for respiratory infection (50, 51). Interpreting spirometric data in a patient with poorly controlled heart failure can be difficult.

In contrast to the clear increase in mortality associated with a diagnosis of heart failure in patients with COPD, it is less clear what the implications of an additional diagnosis of COPD is for patients with HF. In a cohort of nearly 5,000 patients referred between 2000-2016 to a single out-patient clinic with suspected HF in the UK who underwent comprehensive evaluation by echocardiography, natriuretic peptides and spirometry, a diagnosis of COPD, defined as FEV₁/FVC<0.7, was only weakly, and not independently, associated with an increased risk of death amongst patients with HFpEF, and not at all in those with HFrEF (44). Using anonymised electronic records from >50,000 patients with incident HF in primary care in the UK, Lawson and colleagues found that COPD was only associated with an increased risk of death and/or hospitalisations in the most severe cases, with the risk increasing progressively with the use of triple inhaler therapy, the need for oral steroids and the use of long term home oxygen (52).

Recent data from the European Society of Cardiology Heart Failure Long-Term Registry, which enrolled >16,000 patients with heart failure across 211 centres in Europe over a period of 24 months, suggest that COPD increases the risk of cardiovascular mortality (but not all-cause mortality) and re-admissions, particularly due to worsening heart failure, over the
following 12 months (39). Similar results were reported in an analysis of the **Systolic Heart** failure treatment With the **I**- **H**- **E**- **N****i**bradine **T**rial (SHIFT). The composite of cardiovascular deaths or heart failure hospitalisations occurred more often in patients with both HF and COPD, rather than HF alone, but no difference in mortality was observed (41). Whether these associations are related to COPD itself (which might predispose to frequent respiratory infections or arrhythmias, leading to HF admissions) or to other factors (such as a lower use of HF medications in patients with concurrent COPD and HFrEF) is not clear (53-55).

**Therapeutic concerns**

Beta-blockers improve the long-term prognosis of patients with HF due to left ventricular systolic dysfunction (3, 56). However, concerns about the potential for beta-blockers to cause bronchoconstriction and block the effect of sympathomimetic bronchodilators dissuades many from giving these agents in adequate doses, if at all, to patients with concomitant heart failure and COPD (table 3). However, the available clinical evidence suggests that these fears are unfounded. Small randomised trials show that any decline in FEV1 associated with beta-blockers does not translate into worsening symptoms or quality of life in patients with HF and COPD (57, 58). The use of a cardio selective beta-blocker, such as bisoprolol or nebivolol, might be preferred, at least theoretically, when there is concern about tolerability (59, 60).

Perhaps surprisingly, there is accumulating evidence from observational studies and sub-analyses from randomised trials conducted in patients with COPD which suggest that a higher heart rate is associated with an increase in mortality, and that beta-blockers might
reduce exacerbations of COPD and prolong survival (61-63). Some of this apparent benefit might reflect inadvertent, “accidental” treatment of undiagnosed heart failure. A multicenter, prospective, randomized, double-blind, placebo-controlled trial is currently ongoing to test whether metoprolol reduces time to first exacerbation of COPD and of cardiovascular events in patients with moderate to severe COPD (ClinicalTrials.gov Identifier: NCT02587351) (64).

There is no evidence that treatment for COPD improves long-term survival substantially. Beta-agonists can improve lung function tests in patients with COPD, but they might worsen cardiovascular and HF outcomes, especially for patients with HFrEF who are not protected by beta-blockers (65-67). Inhaled steroids may increase the risk of pneumonia (68). Oral steroids may increase sodium and water retention (69). Certainly, a large proportion of patients with COPD can tolerate de-escalation of respiratory therapies, particularly those at low risk of exacerbations. Attempts to identify patients in whom treatments for COPD can be discontinued should be encouraged (70, 71).

Conclusions

Neither COPD nor HF has a robust definition, creating uncertainty about the true prevalence of either condition. Missed diagnoses are common especially when one or other condition provides a seemingly adequate explanation for a patient’s symptoms. However, there is no doubt that these two conditions commonly co-exist.

For patients with COPD, no specific treatment improves survival but they have high rates of cardiovascular events, and often die of the consequences. Greater focus on cardiovascular rather than respiratory disease in patients with COPD might improve outcomes. However,
there is no doubt that appropriate treatment reduces the morbidity and mortality of patients with HFrEF, with or without co-existing COPD.
References


49) Pellicori P, Salekin D, Pan D, Clark AL. This patient is not breathing properly: is this COPD, heart failure, or neither? Expert Rev Cardiovasc Ther. 2017;15:389-396.


Precipitating Clinical Factors, Heart Failure Characterization, and Outcomes in Patients Hospitalized With Heart Failure With Reduced, Borderline, and Preserved Ejection Fraction. JACC Heart Fail. 2016;4:464-72.


<table>
<thead>
<tr>
<th>Study</th>
<th>Year</th>
<th>N</th>
<th>Age</th>
<th>Men-</th>
<th>COPD diagnosis</th>
<th>HF-%</th>
<th>Diuretic-</th>
<th>Oedema -</th>
<th>Current Smoker -</th>
<th>IHD -</th>
<th>AF &amp;</th>
<th>Creatinine</th>
<th>Abnormal NPs -</th>
<th>Criteria used to diagnose HF and prevalence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cross-sectional(^{19})</td>
<td>2001-2003</td>
<td>200</td>
<td>73</td>
<td>58</td>
<td>Clinical or GOLD (59%)</td>
<td>0</td>
<td>22</td>
<td>19</td>
<td>NR</td>
<td>34</td>
<td>9</td>
<td>90 μmol/L</td>
<td>~50</td>
<td>ESC criteria: 26% (15% HFrEF).</td>
</tr>
<tr>
<td>Cross-sectional(^{20})</td>
<td>2006</td>
<td>170</td>
<td>64</td>
<td>75</td>
<td>GOLD Excl.</td>
<td>NR</td>
<td>Excl.</td>
<td>NR</td>
<td>42</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>23</td>
<td>Echocardiography: 3% had LVEF ≤50%</td>
</tr>
<tr>
<td>Prospective, observational(^{21})</td>
<td>2004-2008</td>
<td>140</td>
<td>67</td>
<td>46</td>
<td>GOLD NR</td>
<td>27</td>
<td>19</td>
<td>82</td>
<td>NR</td>
<td>9</td>
<td>92 μmol/L</td>
<td>&gt;50</td>
<td>Echocardiography: 11% had LVEF &lt;45%.</td>
<td></td>
</tr>
<tr>
<td>Prospective, observational(^{22})</td>
<td>NR</td>
<td>218</td>
<td>70</td>
<td>76</td>
<td>GOLD NR</td>
<td>0</td>
<td>22</td>
<td>19</td>
<td>24</td>
<td>17</td>
<td>NR</td>
<td>5% CKD</td>
<td>&gt;50</td>
<td>Echocardiography: 14% HFrEF</td>
</tr>
</tbody>
</table>

Table 1: Screening by natriuretic peptides (NPs) in patients with chronic obstructive pulmonary disease (COPD; only studies with >100 patients). Abnormal NPs includes NT-proBNP >125 ng/l or BNP >35 ng/l. Abbreviations used: N - number of patients; HF – heart failure; HFrEF – heart failure with reduced left ventricular ejection fraction; NR – not reported; Excl = excluded; IHD – ischaemic heart disease; AF – atrial fibrillation; CKD – chronic kidney disease.
<table>
<thead>
<tr>
<th>Study</th>
<th>Size</th>
<th>Year</th>
<th>Country</th>
<th>COPD population and definition</th>
<th>HF definition</th>
<th>Prevalence of HF</th>
<th>CV Therapies in patients with COPD</th>
<th>Outcome findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Divo²⁹</td>
<td>1,664</td>
<td>1997-2009</td>
<td>USA and Spain</td>
<td>Ambulatory, GOLD (≥3: 56%)</td>
<td>Self-reported/medical records</td>
<td>16%</td>
<td>NR</td>
<td>HF increased risk of death (HR: 1.33 (95%CI: 1.06–1.68); p=0.02)</td>
</tr>
<tr>
<td>Cazzola³⁰</td>
<td>341,329</td>
<td>2006</td>
<td>Italy</td>
<td>Primary care; ICD-9</td>
<td>ICD-9</td>
<td>8%</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td>Curendall³¹</td>
<td>11,493</td>
<td>1997-2000</td>
<td>Canada</td>
<td>Gov. database; ICD-9 &amp; prescribed inhaler</td>
<td>ICD-9</td>
<td>19%</td>
<td>Diuretics: 57%; Digoxin: 17% BB: 10%; ACE-I: 34%</td>
<td>Patients diagnosed and treated with COPD are at high risk for CV morbidity and mortality.</td>
</tr>
<tr>
<td>Holguin³²</td>
<td>~47 million</td>
<td>1979-2001</td>
<td>USA</td>
<td>Hospital Discharge; ICD-9</td>
<td>ICD-9</td>
<td>10%</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td>McCullough³³</td>
<td>417</td>
<td>1999-2000</td>
<td>USA/Europe</td>
<td>Emergency department (dyspnoea); self-reported</td>
<td>Framingham and NHANES criteria</td>
<td>21%</td>
<td>HF: Diuretic 53%; Digoxin: 35% ACE-I: 37%; BB: 21%</td>
<td>The emergency physician identified only 37% of HF cases. Patients with HF had higher BNP (mean 587 pg/mL) than those without (108 pg/mL).</td>
</tr>
<tr>
<td>Freixa²⁶</td>
<td>342</td>
<td>2004-06</td>
<td>Spain</td>
<td>First COPD admission: ATS/ERS criteria</td>
<td>Self-reported + Echo 3 months after discharge</td>
<td>13% LVSD (9% unknown) 14 DD ≥grade 3 (10% unknown)</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td>Spece³⁴</td>
<td>2,391</td>
<td>2005-11</td>
<td>USA</td>
<td>Hospital Discharge; ICD-9</td>
<td>ICD-9</td>
<td>23%</td>
<td>NR</td>
<td>CV causes are common reasons for readmission.</td>
</tr>
<tr>
<td>Boudenstein³⁵</td>
<td>404</td>
<td>2001-03</td>
<td>Nederland</td>
<td>Primary care, clinically diagnosed</td>
<td>ESC criteria</td>
<td>21% (previously undiagnosed; 50% had HfPEF)</td>
<td>HF &amp; COPD Diuretic 34% ACE-I/ARB:35% BB: 16%</td>
<td>Newly diagnosed HF was independent predictor of mortality (HR: 2.1; 95% CI: 1.2–3.6; P=0.01).</td>
</tr>
<tr>
<td>Kaszuba³⁶</td>
<td>984 (~3%)</td>
<td>2007</td>
<td>Sweden</td>
<td>Primary and secondary care;</td>
<td>ICD-10 codes</td>
<td>10%</td>
<td>NR</td>
<td>In univariate analysis, mortality in patients with COPD and</td>
</tr>
</tbody>
</table>
Table 2: prevalence of heart failure in patients with COPD. Abbreviations used: BB – beta-blockers; LVEF – left ventricular ejection fraction; HFpEF – heart failure with preserved LVEF; HFrEF – heart failure with reduced LVEF; CV – cardiovascular; LVSD – left ventricular systolic dysfunction; ERS - European Respiratory Society; ATS - American Thoracic Society; ICD - International Classification of Diseases.

<p>| ICD-10 |  |  |  | coexisting heart failure was 7 times higher than in those with COPD alone. |</p>
<table>
<thead>
<tr>
<th>Study</th>
<th>Prevalence of COPD</th>
<th>Size</th>
<th>Year</th>
<th>Country</th>
<th>HF population/diagnosis</th>
<th>Treatment for Heart Failure</th>
<th>Diuretic (COPD vs no COPD)</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>De Blois</td>
<td>17%</td>
<td>4132</td>
<td>2000-2008</td>
<td>Norway</td>
<td>Mixed, &gt;80% HFrEF; ESC guidelines</td>
<td>$BB$ (COPD vs no COPD) 74% vs 84% (p&lt;0.001) Similar: ~90%</td>
<td>90 vs 86% (p=0.002)</td>
<td>COPD independently predicted death (HR, 1.19; 95% CI, 1.02 to 1.39; p=0.03)</td>
</tr>
<tr>
<td>Mentz</td>
<td>10%</td>
<td>4133</td>
<td>2003-2006</td>
<td>USA, Europe, SA</td>
<td>Acute/ LVEF≤40%</td>
<td>$BB$ (COPD vs no COPD) 63% vs 71% (p=0.001) Similar: ~97%</td>
<td>80 vs 85% (p=0.01)</td>
<td>COPD was associated with ACM and CV death/HF only in univariable analysis</td>
</tr>
<tr>
<td>Canepa</td>
<td>19% AHF 14% CHF</td>
<td>16,329</td>
<td>2011-2013</td>
<td>Europe</td>
<td>Mixed, ~70% HFrEF. IV therapy for AHF</td>
<td>CHF: 77 vs 85% (p&lt;0.001) AHF: 51 vs 56% (p&lt;0.001)</td>
<td>CHF: 88 vs 78%; p&lt;0.001</td>
<td>Greater in-hospital mortality in those with COPD (8% vs 5%). COPD was not independent predictor of ACM, but predicted HFrEF.</td>
</tr>
<tr>
<td>Canepa</td>
<td>22%</td>
<td>6,975</td>
<td>2002-2005</td>
<td>Italy</td>
<td>Chronic, ~90% HFrEF/LVEF&lt;40% or HFH in previous 12m</td>
<td>44% vs 71% (p&lt;0.001) Similar: ~85% similar AHF: 64%, similar</td>
<td>93% vs 89% (p&lt;0.001)</td>
<td>COPD was an independent predictor of ACM (HR 1.28, 95% CI 1.15-1.43, p &lt; 0.0001) and hospitalisations</td>
</tr>
<tr>
<td>Tavazzi</td>
<td>11%</td>
<td>6,505</td>
<td>2006-2009</td>
<td>37 Countries</td>
<td>Chronic, HFrEF/LVEF&lt;35%, SR and HFH in prior 12 months</td>
<td>69% vs 92% (p&lt;0.001) Similar (~79%)</td>
<td>89% vs 82% (p&lt;0.001)</td>
<td>The primary endpoint (CV death or HFH), but not ACM, was more frequent in patients with COPD.</td>
</tr>
<tr>
<td>Parissis</td>
<td>25%</td>
<td>4,953</td>
<td>2006-2007</td>
<td>9 Countries</td>
<td>Acute, &gt;50% HFrEF/ ESC guidelines</td>
<td>$BB$ (COPD vs no COPD) 21 vs 24% (p=0.055) Similar: (5%)</td>
<td>35 vs 31% (p=0.006)</td>
<td>Similar in-hospital mortality (~10%).</td>
</tr>
<tr>
<td>Mentz</td>
<td>25%</td>
<td>20,118</td>
<td>2003-2004</td>
<td>USA</td>
<td>Acute, HFrEF/LVSD at admission</td>
<td>52 vs 57% (p&lt;0.001) Similar (54%)</td>
<td>LD: 69 vs 61% (p&lt;0.001)</td>
<td>COPD increased in-hospital non CV mortality, but not</td>
</tr>
<tr>
<td></td>
<td>COPD diagnosed by spirometry</td>
<td>post-discharge mortality.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------------</td>
<td>------------------------------------------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cuthbert(^4)</td>
<td>50% 3,514 2000-2016 UK Chronic at first visit, \textasciitilde 25% HFpEF/reduced LVEF or NT-proBNP&gt;400 ng/l</td>
<td>54% vs 62% Similar: 71% vs 72% LD: Similar: 72% vs 70% COPD weakly associated with ACM in HFrEF, but not HFpEF.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jacob(^5)</td>
<td>26% 8,099 2009-2012 Spain Acute, 38% HFrEF/clinical and radiological Admission: 30% vs 45% (p&lt;0.001) Admission: Similar (\textasciitilde 56%) LD: 75% vs 68% (p&lt;0.001) COPD only associated with readmissions at 30 days.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Iversen(^6)</td>
<td>35% (vs 22% self-reported) 532 2001-2004 Denmark Acute, 42% HFpEF/requiring IV diuretic 17% vs 32% (p=0.002) Similar (\textasciitilde 35%) 71% vs 64% (p=0.18) PFTs provide prognostic information in HF.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Plesner(^7)</td>
<td>39%; 573 2009-2011 Denmark Chronic at first visit/LVEF&lt;45% Similar: 75% vs 78% (p=0.03) 88% vs 94% (p&lt;0.01) LD: 64% vs 48% (p&lt;0.01) Abnormal spirometry predicted ACM.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yoshihisa(^8)</td>
<td>28% 378 2009-2012 Japan Acute, \textasciitilde 50% HFpEF/Framingham criteria 67% vs 79% (p=0.014) Similar (87%) NR PFTs provide prognostic information in HF.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 3: prevalence of COPD in patients with HF, in selected recent registries and clinical trials. Abbreviations used: ACM - all-cause mortality; LD – loop diuretic, BB – beta-blockers; LVEF – left ventricular ejection fraction; HFpEF – heart failure with preserved LVEF; HFrEF – heart failure with reduced LVEF; CV – cardiovascular; HFH – heart failure hospitalisations. PFTs – pulmonary function tests; IV – intravenous.